Endologix Inc /de/ (ELGX) Files Form 4 Insider Selling : Gregory D Waller Sells 7,800 Shares

Endologix Inc /de/ (ELGX): Gregory D Waller , director of Endologix Inc /de/ sold 7,800 shares on Jun 3, 2016. The Insider selling transaction was reported by the company on Jun 6, 2016 to the Securities and Exchange Commission. The shares were sold at $12.86 per share for a total value of $100,308.00 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 2, 2016, David M. Jennings (VP-Human Resources) sold 957 shares at $12.55 per share price.On Jun 2, 2016, James Edward Machek (VP-Research & Development) sold 957 shares at $12.55 per share price.Also, On Jun 2, 2016, Robert D Mitchell (President) sold 2,294 shares at $12.55 per share price.On Jun 2, 2016, Joseph A. Dejohn (General Manager, Asia & Pac) sold 957 shares at $12.55 per share price.

Shares of Endologix (ELGX) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.3 points or -2.30% at $12.76 with 28,37,794 shares getting traded. Post opening the session at $13, the shares hit an intraday low of $12.63 and an intraday high of $13.12 and the price vacillated in this range throughout the day. The company has a market cap of $1,044 M and the number of outstanding shares has been calculated to be 8,18,19,293 shares. The 52-week high of Endologix is $16.99 and the 52-week low is $6.505.

Endologix Money Flow Index Chart

Company has been under the radar of several Street Analysts.Endologix is Reiterated by RBC Capital Mkts to Outperform and the brokerage firm has raised the Price Target to $ 15 from a previous price target of $11 .The Rating was issued on May 10, 2016.Endologix is Resumed by JP Morgan to Overweight. The Rating was issued on Apr 4, 2016.

Endologix Inc. is engaged in developing manufacturing marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms: traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS) its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The Company’s EVAS product is based on the Nellix platform to seal the aneurysm and provide blood flow to the legs through two blood lumens.

Leave a Reply

Endologix - Is it time to Sell?

Top Brokerage Firms are advising their investors on Endologix. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.